Ocular immunology and inflammation · 2022
The Complete Success in Refractory Mooren's Ulcer Treated with Infliximab.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Çakmak Ayşe İdil, Akova Yonca, Yıldırım Nilgün
Аннотация
PURPOSE: To describe the management and outcome of two extremely rare and painful cases of Mooren's ulcer, an idiopathic peripheral autoimmune-associated ulcerative corneal disease.
METHODS: Case report with literature review on the management of ocular inflammation in Mooren's ulcer.
RESULTS: A 47-year-old female and a 76-year-old female presented with progressive bilateral Mooren's ulcer that were refractory to conventional immunosuppressive therapy. Following treatment with infliximab, an anti-tumor necrosis factor alpha, a significant improvement in disease progression was observed, with no corneal thinning or perforation at follow-ups.
CONCLUSION: This case report highlights how infliximab can be effective in cases with Mooren's ulcer refractory to conventional therapies.
METHODS: Case report with literature review on the management of ocular inflammation in Mooren's ulcer.
RESULTS: A 47-year-old female and a 76-year-old female presented with progressive bilateral Mooren's ulcer that were refractory to conventional immunosuppressive therapy. Following treatment with infliximab, an anti-tumor necrosis factor alpha, a significant improvement in disease progression was observed, with no corneal thinning or perforation at follow-ups.
CONCLUSION: This case report highlights how infliximab can be effective in cases with Mooren's ulcer refractory to conventional therapies.